Document 2857
 DOCN  M94A2857
 TI    Retrospective study of zidovudine (ZDV) or didanosine (ddI) monotherapy
       or zalcitabine plus zidovudine (ddC + ZDV) combination therapy in
       patients with early AIDS.
 DT    9412
 AU    Barr M; Torres RA; St. Vincent's Hospital and Medical Center, NYC.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):209 (abstract no. PB0266). Unique
       Identifier : AIDSLINE ICA10/94369718
 AB    OBJECTIVE: To assess the relative efficacies of zidovudine (ZDV) and
       didanosine (ddI) monotherapies compared to combination therapy with
       zalcitabine (ddC) plus zidovudine (ZDV) in 150 patients with early AIDS.
       METHODS: One hundred and fifty ZDV-experienced persons attending the St.
       Vincent's Hospital out-patient HIV clinic who either (1) remained on
       zidovudine (ZDV) monotherapy or who (2) switched to didanosine (ddI)
       monotherapy or (3) to combination therapy with zalcitabine plus
       zidovudine (ddC + ZDV) were followed. The primary endpoints in this
       study were development of new opportunistic infections and death.
       Differences in rates of adverse events were also compared. RESULTS:
       Patients in the 3 groups were similar in terms of baseline demographics.
       Mean baseline CD4 count was 124 cells/mm3; mean duration of prior
       zidovudine, 15.5 months. Mean follow-up time was 30 weeks. Both
       time-adjusted mean number of hospitalizations (ZDV, 22.1; ddI, 17.0; ddC
       + ZDV, 19.3) and rate of new opportunistic infections (ZDV, 13.8%; ddI,
       9.7%; ddC + ZDV, 24.1%) were lowest in the didanosine (ddI) group. Rate
       of adverse events requiring discontinuation of therapy were higher in
       the combination group (25.1%) than in the ddI (17.7%) or ZDV (15.8%)
       groups. CONCLUSION: In ZDV-experienced patients with early AIDS,
       switching to didanosine (ddI) may confer a clinical benefit as measured
       by a reduced number of hospitalizations and of new opportunistic
       infections. Combination therapy with zalcitabine plus zidovudine (ddC +
       ZDV), however, appears inferior to both ZDV and ddI monotherapies, and
       results in considerably more adverse reactions.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY  AIDS-Related
       Opportunistic Infections/PREVENTION & CONTROL  Comparative Study
       Didanosine/ADVERSE EFFECTS/*THERAPEUTIC USE  Drug Therapy, Combination
       Human  Retrospective Studies  Treatment Outcome
       Zalcitabine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).